Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies for hematologic diseases, with a lead focus on the small molecule CXCR4 antagonist burixafor (GPC-100). The Exicure news feed highlights how the company advances this program across multiple indications and how its financial and corporate decisions affect the XCUR stock story.
Readers can follow updates on Exicure’s clinical trials, including an open-label, multicenter Phase 2 study of burixafor in combination with propranolol and G-CSF in patients with multiple myeloma undergoing autologous hematopoietic cell or stem cell transplantation. Company announcements describe topline and interim results, rates of successful CD34+ cell mobilization, engraftment outcomes for participants who proceed to transplant, and safety observations for the burixafor-based regimen.
News items also cover pipeline expansion plans, where Exicure discusses potential use of burixafor in sickle cell disease, rare diseases requiring autologous transplant, cell and gene therapy settings, and as a potential chemosensitizing agent in acute myeloid leukemia (AML). These releases outline how mobilizing hematopoietic or malignant cells from the bone marrow niche into peripheral blood could support transplant procedures or enhance chemotherapy effectiveness.
In addition, the XCUR news stream includes financial results and going concern disclosures, detailing quarterly cash balances, research and development and general and administrative expenses, and management’s assessment that additional financing is needed to fund operations and strategic alternatives. Corporate governance and listing-related developments, such as Nasdaq compliance notices, annual meeting information, and board composition changes, are also reported.
Investors and followers of Exicure can use this page to monitor clinical data presentations, strategic updates related to the acquisition of GPCR Therapeutics USA Inc., and regulatory or capital markets filings that shape the company’s hematology-focused trajectory. Bookmark this feed to review new press releases and regulatory-linked news as they are published.
Exicure (Nasdaq: XCUR) announced publication in Annals of Hematology reporting Phase 2 data for burixafor (GPC-100/TG-0054), a selective CXCR4 inhibitor. In a 12-participant study, 11 of 12 (92%) collected ≥5.0×10⁶ CD34+ cells/kg within two sessions; six achieved this in one session. Median neutrophil and platelet engraftment were 12 and 22 days. Peak CD34+ mobilization occurred within one hour, enabling same-day leukapheresis and marked lymphocyte increases (up to 11-fold in MM patients). Burixafor was generally well tolerated with two low-grade treatment-related adverse events. Exicure is advancing further Phase 2 studies including a propranolol combination.
Exicure (Nasdaq: XCUR) will present a poster at the 2026 Tandem Meetings (ASTCT/CIBMTR) in Salt Lake City on February 5, 2026, summarizing results from its open-label, multicenter Phase 2 trial (NCT05561751) of burixafor for hematopoietic progenitor cell mobilization in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.
The company reported positive topline data showing 89.7% of patients met the trial primary endpoint; burixafor was given with propranolol and G-CSF and enabled same-day administration and leukapheresis with a reported favorable safety profile.
Exicure (Nasdaq: XCUR) reported positive topline Phase 2 results for burixafor (GPC-100) combined with propranolol and G-CSF for hematopoietic progenitor cell mobilization in multiple myeloma.
In the open-label, multicenter trial (NCT05561751), 17 of 19 participants (89.5%) collected ≥2×10⁶ CD34+ cells/kg within two leukapheresis sessions; two required an additional session. Median time to neutrophil engraftment was 13 days and platelet engraftment 17.5 days. Peak peripheral CD34+ levels occurred within one hour after dosing. Among 16 participants with prior daratumumab, 14 (87.5%) met the primary endpoint. Burixafor with propranolol and G-CSF was well tolerated with no burixafor-related adverse events >Grade 2.
Exicure (Nasdaq: XCUR) reported third quarter 2025 results for the quarter ended September 30, 2025.
Key figures: cash and cash equivalents $4.4M (Sept 30, 2025 vs $12.5M on Dec 31, 2024), R&D $0.9M, G&A $1.5M, and net loss $2.4M for Q3 2025. The company recorded a $246K loss from a contingent liability change and a $155K gain related to a self-insured retainer settlement.
Management stated cash is not sufficient to fund operations and said substantial additional financing is needed in the short term.
Exicure (Nasdaq: XCUR) announced that completed Phase 2 data for burixafor, a CXCR4 antagonist, will be presented orally at the 67th ASH Annual Meeting on December 8, 2025. The oral presentation (Abstract 1050) reports results from an open-label, multicenter Phase 2 trial (NCT05561751) of burixafor plus G-CSF and propranolol to mobilize hematopoietic progenitor cells in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.
The presentation highlights an excellent safety profile, same-day administration with leukapheresis, and that 18 of 19 patients who chose transplant proceeded to AHCT; many enrolled patients had prior daratumumab exposure. Presenter: Dr. Jack Khouri. Session: Cell Collection and Manufacturing; 5:45–6:00pm EST, Hyatt Regency Ballroom R.
Exicure (Nasdaq: XCUR) reported progress on its lead program burixafor (GPC-100), highlighting that an ongoing Phase 2 multiple myeloma study achieved the primary endpoint in all evaluable patients (10/10) and that the clinical database is locked with topline data expected in Q4 2025. The company is preparing for potential Phase 3 planning and expanding development into sickle cell disease (investigator-sponsored trial discussions) and a planned Phase 1 AML chemosensitization study. Exicure also announced new senior drug-development hires to support clinical and translational execution.
Exicure (Nasdaq: XCUR) reported Q2 2025 financial results, highlighting significant challenges in its financial position. The company's cash and cash equivalents decreased to $7.9 million as of June 30, 2025, down from $12.5 million at the end of 2024.
Following the acquisition of GPCR Therapeutics USA, R&D expenses increased to $0.9 million (from $0 in Q2 2024), while G&A expenses rose to $1.5 million (from $1.2 million). The company reported a net loss of $2.6 million for Q2 2025, significantly higher than the $0.6 million loss in Q2 2024.
Management has expressed serious concerns about the company's ability to continue operations, stating that current cash reserves are insufficient and substantial additional financing is urgently needed.
Exicure (Nasdaq: XCUR), a clinical-stage biotechnology company focused on hematologic disease therapeutics, has successfully regained compliance with Nasdaq's listing requirements. The company received confirmation from Nasdaq's Listing Qualifications Department after filing its required Form 10-Q for Q1 2025.
The compliance was achieved on July 1, 2025, following the submission of periodic reports to the SEC, resolving previous filing deficiencies under Listing Rule 5250(c)(1).
Exicure (Nasdaq: XCUR) has completed the last patient visit in its Phase 2 clinical trial evaluating GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients. The study assesses GPC-100's ability to improve CD34+ hematopoietic stem cell mobilization for autologous stem cell transplant (ASCT).
Key highlights include GPC-100's differentiated rapid mobilization time of just 45 minutes before collection, compared to traditional overnight procedures. The company expects topline results in Q4 2025. Beyond multiple myeloma, Exicure plans a Phase 1 study in acute myeloid leukemia and is exploring potential collaborations for cell and gene therapy applications.
Exicure (Nasdaq: XCUR) reported Q1 2025 financial results, posting a net income of $3.0 million compared to a net loss of $0.8 million in Q1 2024. The company's cash position stood at $10.4 million as of March 31, 2025, down from $12.5 million at the end of 2024.
The quarter's performance was primarily driven by a $6 million gain from early lease termination in Chicago, offset by increased operating expenses following the GPCR USA acquisition. R&D expenses increased to $0.8 million, while G&A expenses rose to $2.2 million.
Notably, management expressed significant concern about the company's financial sustainability, stating that current cash reserves are insufficient to fund ongoing operations and substantial additional financing is urgently needed.
FAQ
What is the current stock price of Exicure (XCUR)?
What is the market cap of Exicure (XCUR)?
